AzTrials
AzTrials

Colorectal Adenoma and CarcinomaRM-CAR-MRPNCT07683312

Recurrence Mechanisms of Colorectal Adenoma After Resection and a Multi-Omics Research Protocol

An observational study of Colorectal Adenoma and Carcinoma, run by Zhongshan Hospital Xiamen University.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Official record
Search all trials

Trial summary

We aim to establish a single-cell atlas of primary adenomas, recurrent adenomas, and paired normal mucosa, identify recurrence-associated cell subpopulations and transcriptional pathways, and construct a risk prediction model for recurrence (integrating multi-omics features and clinical variables). Read more about this study

Who is it for?
Any age
Conditions the study is for
Colorectal Adenoma and Carcinoma
How many people
30 participants
Where
No sites listed yet
Study dates
27 Jun 2026to 30 Dec 2029
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Patients who have undergone colonoscopy

Who may be able to join

  • Patients with colorectal adenoma confirmed by initial endoscopic examination and pathological diagnosis.

Who cannot join

  • Use of antibiotics within the past 2 weeks; Patients without colorectal adenoma; Patients with familial adenomatous polyposis; Patients with special dietary habits, such as vegetarians, alcoholics, binge eaters, or anorexic patients, etc.

About this study

We aim to establish a single-cell atlas of primary adenomas, recurrent adenomas, and paired normal mucosa, identify recurrence-associated cell subpopulations and transcriptional pathways, and construct a risk prediction model for recurrence (integrating multi-omics features and clinical variables). Ultimately, we propose a panel of biomarkers that can be used to optimize follow-up strategies and guide potential microbiome-based interventions.

Under the premise of meeting routine clinicopathological requirements, we will collect tissue samples from 30 patients with colorectal adenomas. Each collected adenoma sample will be divided into three equal portions for scRNA-seq, scATAC-seq, and microbiome diversity sequencing, respectively. Two years after sampling, enrolled patients will undergo follow-up colonoscopy. Those in whom adenomas are detected will be classified as the recurrence group, while those without adenomas will be classified as the non-recurrence group. Sequencing data will be jointly analyzed in conjunction with clinical medical records. The tissue specimens obtained will not affect routine diagnosis or treatment outcomes.

Read the detailed description

This study aims to: (1) establish a single-cell atlas of primary adenomas, recurrent adenomas, and paired normal mucosa, and identify recurrence-associated cell subpopulations and transcriptional pathways; (2) construct a recurrence risk prediction model integrating multi-omics features and clinical variables, and propose a panel of biomarkers for optimizing follow-up strategies and guiding potential microbiome-based interventions. The study plans to collect colorectal adenoma tissues from 30 patients who are first diagnosed by endoscopy. Each specimen will be equally divided into three portions for single-cell RNA sequencing (scRNA-seq), single-cell ATAC sequencing (scATAC-seq), and microbiome diversity sequencing. Two years after sampling, all enrolled patients will undergo follow-up colonoscopy; those found to have adenomas will be assigned to the recurrence group, while those without adenomas will be assigned to the non-recurrence group. By integrating multi-omics data for association analysis between the two groups, we aim to elucidate the key drivers of post-polypectomy recurrence, and explore whether there exists an interpretable causal chain linking host epigenetic status, cellular transcriptional programs, and mucosa-associated microbiota that can explain recurrence risk and yield translatable biomarkers. A total of 30 cases will be included. Inclusion criteria: patients with colorectal adenoma confirmed by initial endoscopic examination and pathology. Exclusion criteria: (1) use of antibiotics within the past two weeks; (2) patients without colorectal adenoma; (3) patients with familial adenomatous polyposis; (4) patients with special dietary habits such as vegetarianism, alcoholism, binge eating, or anorexia. Under the premise of meeting routine clinicopathological requirements, 30 colorectal adenoma tissue samples will be collected and each sample will be divided into three equal parts for scRNA-seq, scATAC-seq, and microbiome diversity sequencing. Two years after sampling, patients will undergo follow-up colonoscopy; those with adenomas detected will be classified as the recurrence group, and those without as the non-recurrence group. Through integrated multi-omics correlation analysis, a single-cell integrative atlas of "mucosal microbiota - host epigenome (scATAC) - transcriptome (scRNA)" will be constructed to decipher the key cell states, regulatory elements, and microenvironmental signals underlying post-adenomectomy recurrence, and to establish a multidimensional biomarker panel for risk stratification. Statistical analysis will be performed using SPSS 26.0. Univariate statistical tests will be applied to compare differences between groups. For normally distributed data, ANOVA (for multiple groups) and Student's t-test (for two groups) will be used; for non-normally distributed data, the Kruskal-Wallis H test (for multiple groups) and Mann-Whitney U test (for two groups) will be employed.

Medical subject headings
Carcinoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07683312
Study groupRoleWhat they receive
The study plans to collect colorectal adenoma tissues from 30 patients initially detected by endoscoThe study plans to collect colorectal adenoma tissues from 30 patients initially detected by endoscopy, and perform scRNA-seq, scATAC-seq, and microbiome diversity sequencing on each sample, respectively. Two years after sampling, all enrolled patients will undergo follow-up colonoscopy; those found to have adenomas will be assigned to the recurrence group, while those without adenomas will be assigned to the non-recurrence group. By integrating multi-omics data for association analysis between the recurrence and non-recurrence groups, we aim to investigate the main driving factors of post-polypectomy recurrence, and to explore whether there exists an interpretable causal chain linking host epigenetic status, cellular transcriptional programs, and mucosa-associated microbiota that can explain recurrence risk and yield translatable biomarkers.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Multi-Omics Research Protocol on Recurrence Mechanisms After Colorectal Adenoma Resection

    Whether Recurrence Occurred

    Measured: December 2029

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jul 2026
  2. Study start27 Jun 2026 (estimated)
  3. Primary completion30 Aug 2029 (estimated)
  4. Study completion30 Dec 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07683312
Sponsor's protocol ID
ZhongshanHXU
Acronym
RM-CAR-MRP
Status last verified
Jun 2026
First submitted
28 Jun 2026
Last updated
6 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Uncertain research data

Questions about this trial

What is this clinical trial studying?

An observational study of Colorectal Adenoma and Carcinoma, run by Zhongshan Hospital Xiamen University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 6 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Multi-Omics Research Protocol on Recurrence Mechanisms After Colorectal Adenoma Resection (time frame: December 2029). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2026; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in